html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

methylcob(III)alaminFinding

methylcob(III)alamin has no detected effect on progression-free survival

no difference foundVery limited evidenceFinding

01 · The sentence it was drawn from

“Neither PFS nor OS was significantly different between HDIME group and control group(P>0.05).”

Quoted verbatim from [Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].

This finding among the 2 findings on its endpoint

methylcob(III)alamin

Progression-free survival

no difference found

Who: 65 newly diagnosed multiple myeloma patients receiving bortezomib-based chemotherapy in both arms
Dose studied: high-dose intravenous mecobalamin, dose not stated in the abstract, added to bortezomib-based chemotherapy

Very limited evidencePMID 28446297 · 2017

02 · The study

Study: RCT
Duration: not reported

Evidence, by strength

strong
moderate
limited
very limitedthis finding
insufficient

03 · The paper

Zhongguo shi yan xue ye xue za zhi

[Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].

2017PMID 28446297doi 10.7534/j.issn.1009-2137.2017.02.031

What else it reported1 finding · 1 compound · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZCQTTN7M3CTSM236N7P10K